INTRODUCTION
Patients with psychotic or depressive disorders have an increased risk of developing metabolic syndrome, not only because of their unhealthy lifestyle (sedentary habits, inadequate diet and smoking) but also because of the negative impact of antipsychotic agents (specially clozapine and olanzapine) on several metabolic features. These include overweight/obesity, dyslipidemia, development of new-onset type 2 diabetes, worsening of pre-existing diabetes and diabetic ketoacidosis (DKA). DISCUSSION Approximately 35% of the cases of diabetes associated with antipsychotic agents present as DKA. The characteristics of the patient and his HbA1c suggests he had an undiagnosed type 2 diabetes, which manifested as a diabetic ketoacidosis. The temporal relationship between the introduction of olanzapine and the development of diabetic ketoacidosis and the possibility of an adequate glycemic control with oral antidiabetic drugs after discontinuation of antipsychotic agents suggest a direct metabolic effect. The mechanisms remain unclear, but histamine, muscarinic and serotonergic receptors seem to be implicated.
CONCLUSION This case report illustrates one serious complication of antipsychotic agents and stresses the importance of an evaluation of the metabolic risk and an individualized selection of the antipsychotic agent for these patients. Hospital discharge
